You are here

  • Home
  • Archive
  • Volume 5, Issue 2
  • Gemfibrozil reduced the risk for coronary events in men with coronary artery disease and low levels of high density lipoprotein cholesterol

Article Text

Article menu
Download PDFPDF
Therapeutics
Gemfibrozil reduced the risk for coronary events in men with coronary artery disease and low levels of high density lipoprotein cholesterol

https://doi.org/10.1136/ebm.5.2.49

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (1999) N Engl J Med 341, 410. Rubins HB, Robins SJ, Collins D, et al,. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.. Aug 5;. :. –18.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: Is gemfibrozil effective for secondary prevention of coronary artery disease (CAD) events in men with low levels of both high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol?

    Design

    Randomised {allocation concealed*},† blinded (patients, outcome assessors, and study personnel),* placebo controlled trial with median follow up of 5.1 years (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial [VA-HIT]).

    Setting

    20 Veterans Affairs medical centres in the United States.

    Patients

    2531 men who were <74 years of age (mean age 64 y); had a documented history of CAD; had no serious comorbid conditions; and had an HDL cholesterol level ≤40 mg/dl (1.0 mmol/l), an LDL cholesterol level ≤140 mg/dl (3.6 mmol/l), and a triglyceride level ≤300 mg/dl …

    View Full Text